Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
<h4>Background</h4>Essential information regarding efficacy and safety of vitamin K-antagonists (VKA) treatment for atrial fibrillation (AF) in non-dialysis dependent chronic kidney disease (CKD) is still lacking in current literature. The aim of our study was to compare the risks of str...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ea0d39f8c4cc497d8666ea7f4ae219e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ea0d39f8c4cc497d8666ea7f4ae219e3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ea0d39f8c4cc497d8666ea7f4ae219e32021-11-18T08:19:50ZEfficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.1932-620310.1371/journal.pone.0094420https://doaj.org/article/ea0d39f8c4cc497d8666ea7f4ae219e32014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24817475/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Essential information regarding efficacy and safety of vitamin K-antagonists (VKA) treatment for atrial fibrillation (AF) in non-dialysis dependent chronic kidney disease (CKD) is still lacking in current literature. The aim of our study was to compare the risks of stroke or transient ischemic attack (TIA) and major bleeds between patients without CKD (eGFR >60 ml/min), and those with moderate (eGFR 30-60 ml/min), or severe non-dialysis dependent CKD (eGFR <30 ml/min).<h4>Methods</h4>We included 300 patients without CKD, 294 with moderate, and 130 with severe non-dialysis dependent CKD, who were matched for age and sex. Uni- and multivariate Cox regression analyses were performed reporting hazard ratios (HRs) for the endpoint of stroke or TIA and the endpoint of major bleeds as crude values and adjusted for comorbidity and platelet-inhibitor use.<h4>Results</h4>Overall, 6.2% (45/724, 1.7/100 patient years) of patients developed stroke or TIA and 15.6% (113/724, 4.8/100 patient years) a major bleeding event. Patients with severe CKD were at high risk of stroke or TIA and major bleeds during VKA treatment compared with those without renal impairment, HR 2.75 (95%CI 1.25-6.05) and 1.66 (95%CI 0.97-2.86), or with moderate CKD, HR 3.93(1.71-9.00) and 1.86 (95%CI 1.08-3.21), respectively. These risks were similar for patients without and with moderate CKD. Importantly, both less time spent within therapeutic range and high INR-variability were associated with increased risks of stroke or TIA and major bleeds in severe CKD patients.<h4>Conclusions</h4>VKA treatment for AF in patients with severe CKD has a poor safety and efficacy profile, likely related to suboptimal anticoagulation control. Our study findings stress the need for better tailored individualised anticoagulant treatment approaches for patients with AF and severe CKD.Judith KooimanNienke van ReinBas SpaansKoen A J van BeersJonna R BankWilke R van de PeppelAntonio Iglesias del SolSuzanne C CannegieterTon J RabelinkGregory Y H LipFrederikus A KlokMenno V HuismanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 5, p e94420 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Judith Kooiman Nienke van Rein Bas Spaans Koen A J van Beers Jonna R Bank Wilke R van de Peppel Antonio Iglesias del Sol Suzanne C Cannegieter Ton J Rabelink Gregory Y H Lip Frederikus A Klok Menno V Huisman Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| description |
<h4>Background</h4>Essential information regarding efficacy and safety of vitamin K-antagonists (VKA) treatment for atrial fibrillation (AF) in non-dialysis dependent chronic kidney disease (CKD) is still lacking in current literature. The aim of our study was to compare the risks of stroke or transient ischemic attack (TIA) and major bleeds between patients without CKD (eGFR >60 ml/min), and those with moderate (eGFR 30-60 ml/min), or severe non-dialysis dependent CKD (eGFR <30 ml/min).<h4>Methods</h4>We included 300 patients without CKD, 294 with moderate, and 130 with severe non-dialysis dependent CKD, who were matched for age and sex. Uni- and multivariate Cox regression analyses were performed reporting hazard ratios (HRs) for the endpoint of stroke or TIA and the endpoint of major bleeds as crude values and adjusted for comorbidity and platelet-inhibitor use.<h4>Results</h4>Overall, 6.2% (45/724, 1.7/100 patient years) of patients developed stroke or TIA and 15.6% (113/724, 4.8/100 patient years) a major bleeding event. Patients with severe CKD were at high risk of stroke or TIA and major bleeds during VKA treatment compared with those without renal impairment, HR 2.75 (95%CI 1.25-6.05) and 1.66 (95%CI 0.97-2.86), or with moderate CKD, HR 3.93(1.71-9.00) and 1.86 (95%CI 1.08-3.21), respectively. These risks were similar for patients without and with moderate CKD. Importantly, both less time spent within therapeutic range and high INR-variability were associated with increased risks of stroke or TIA and major bleeds in severe CKD patients.<h4>Conclusions</h4>VKA treatment for AF in patients with severe CKD has a poor safety and efficacy profile, likely related to suboptimal anticoagulation control. Our study findings stress the need for better tailored individualised anticoagulant treatment approaches for patients with AF and severe CKD. |
| format |
article |
| author |
Judith Kooiman Nienke van Rein Bas Spaans Koen A J van Beers Jonna R Bank Wilke R van de Peppel Antonio Iglesias del Sol Suzanne C Cannegieter Ton J Rabelink Gregory Y H Lip Frederikus A Klok Menno V Huisman |
| author_facet |
Judith Kooiman Nienke van Rein Bas Spaans Koen A J van Beers Jonna R Bank Wilke R van de Peppel Antonio Iglesias del Sol Suzanne C Cannegieter Ton J Rabelink Gregory Y H Lip Frederikus A Klok Menno V Huisman |
| author_sort |
Judith Kooiman |
| title |
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| title_short |
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| title_full |
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| title_fullStr |
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| title_full_unstemmed |
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| title_sort |
efficacy and safety of vitamin k-antagonists (vka) for atrial fibrillation in non-dialysis dependent chronic kidney disease. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/ea0d39f8c4cc497d8666ea7f4ae219e3 |
| work_keys_str_mv |
AT judithkooiman efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT nienkevanrein efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT basspaans efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT koenajvanbeers efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT jonnarbank efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT wilkervandepeppel efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT antonioiglesiasdelsol efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT suzanneccannegieter efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT tonjrabelink efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT gregoryyhlip efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT frederikusaklok efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease AT mennovhuisman efficacyandsafetyofvitaminkantagonistsvkaforatrialfibrillationinnondialysisdependentchronickidneydisease |
| _version_ |
1718421956960714752 |